Cytek Biosciences (CTKB) Competitors $3.36 -0.02 (-0.45%) As of 11:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTKB vs. TXG, TRNS, EYPT, ALNT, LAB, AEHR, SENS, QSI, QTRX, and MASSShould you be buying Cytek Biosciences stock or one of its competitors? The main competitors of Cytek Biosciences include 10x Genomics (TXG), Transcat (TRNS), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Standard BioTools (LAB), Aehr Test Systems (AEHR), Senseonics (SENS), Quantum-Si (QSI), Quanterix (QTRX), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Cytek Biosciences vs. Its Competitors 10x Genomics Transcat Eyepoint Pharmaceuticals Allient Standard BioTools Aehr Test Systems Senseonics Quantum-Si Quanterix 908 Devices 10x Genomics (NASDAQ:TXG) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends. Does the media prefer TXG or CTKB? In the previous week, 10x Genomics had 6 more articles in the media than Cytek Biosciences. MarketBeat recorded 7 mentions for 10x Genomics and 1 mentions for Cytek Biosciences. 10x Genomics' average media sentiment score of 0.63 beat Cytek Biosciences' score of 0.00 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings and valuation, TXG or CTKB? Cytek Biosciences has lower revenue, but higher earnings than 10x Genomics. Cytek Biosciences is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.74-$182.63M-$1.30-10.45Cytek Biosciences$200.45M2.12-$6.02M-$0.09-37.28 Which has more risk and volatility, TXG or CTKB? 10x Genomics has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Do insiders & institutionals hold more shares of TXG or CTKB? 84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 9.4% of 10x Genomics shares are held by insiders. Comparatively, 10.3% of Cytek Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is TXG or CTKB more profitable? Cytek Biosciences has a net margin of -5.71% compared to 10x Genomics' net margin of -25.14%. Cytek Biosciences' return on equity of -2.90% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-25.14% -23.22% -18.02% Cytek Biosciences -5.71%-2.90%-2.30% Do analysts recommend TXG or CTKB? 10x Genomics presently has a consensus price target of $13.23, suggesting a potential downside of 2.62%. Cytek Biosciences has a consensus price target of $5.60, suggesting a potential upside of 66.92%. Given Cytek Biosciences' higher probable upside, analysts plainly believe Cytek Biosciences is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 5 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.42Cytek Biosciences 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Summary10x Genomics beats Cytek Biosciences on 9 of the 16 factors compared between the two stocks. Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTKB vs. The Competition Export to ExcelMetricCytek BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$426.21M$3.07B$5.69B$9.49BDividend YieldN/A2.44%4.05%3.99%P/E Ratio-37.3821.0428.0020.03Price / Sales2.12251.99397.6083.98Price / Cash93.6541.9636.1958.45Price / Book1.098.268.655.83Net Income-$6.02M-$55.19M$3.24B$258.39M7 Day Performance1.67%5.52%3.62%2.50%1 Month Performance3.87%18.20%11.16%12.85%1 Year Performance-46.58%7.33%35.16%21.38% Cytek Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTKBCytek Biosciences2.5624 of 5 stars$3.36-0.4%$5.60+66.9%-45.9%$426.21M$200.45M-37.38500News CoverageGap DownTXG10x Genomics4.1217 of 5 stars$12.47-2.6%$14.13+13.3%-28.2%$1.54B$624.66M-9.591,240Analyst RevisionTRNSTranscat2.4264 of 5 stars$86.45-0.2%$112.20+29.8%-42.0%$805.71M$278.42M55.421,245News CoverageEYPTEyepoint Pharmaceuticals1.2338 of 5 stars$10.17-1.8%$25.67+152.4%+11.9%$699.81M$56.04M-4.22120ALNTAllient1.7146 of 5 stars$39.11+1.3%$31.00-20.7%+41.2%$662.09M$516.06M66.292,525LABStandard BioTools3.6289 of 5 stars$1.25-5.3%$2.50+100.0%-36.1%$474.78M$169.69M-3.57620Positive NewsUpcoming EarningsAEHRAehr Test Systems1.9519 of 5 stars$13.86-1.8%$25.00+80.4%+22.8%$412.61M$58.97M-106.6190SENSSenseonics2.3666 of 5 stars$0.49-0.8%$1.70+244.9%+22.8%$322.46M$23.68M-3.7990Positive NewsQSIQuantum-Si1.9411 of 5 stars$1.73flat$3.48+100.9%+66.4%$317.45M$3.44M-2.54150Gap UpQTRXQuanterix2.7379 of 5 stars$6.05+2.7%$13.50+123.1%-62.6%$302.20M$137.42M-4.65460Analyst RevisionMASS908 Devices1.3786 of 5 stars$6.72-3.2%$5.33-20.6%+31.4%$240.98M$59.63M-12.4460Positive News Related Companies and Tools Related Companies 10x Genomics Alternatives Transcat Alternatives Eyepoint Pharmaceuticals Alternatives Allient Alternatives Standard BioTools Alternatives Aehr Test Systems Alternatives Senseonics Alternatives Quantum-Si Alternatives Quanterix Alternatives 908 Devices Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTKB) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
